生物技术
Search documents
“十四五”以来中央企业资产总额从不到70万亿元增至超过90万亿元
Mei Ri Jing Ji Xin Wen· 2025-09-17 13:31
Core Insights - The central enterprises in China have shown significant growth in assets and profits during the "14th Five-Year Plan" period, with total assets increasing from less than 70 trillion yuan to over 90 trillion yuan and total profits rising from 1.9 trillion yuan to 2.6 trillion yuan, reflecting an annual growth rate of 7.3% and 8.3% respectively [2][3] Group 1: High-Quality Development - The quality and efficiency of central enterprises have improved, with the operating income profit margin increasing from 6.2% to 6.7% and labor productivity rising from 594,000 yuan to 817,000 yuan per employee per year [2][3] - Central enterprises have made significant strides in technological innovation, with R&D expenditure exceeding 1 trillion yuan for three consecutive years and the investment intensity increasing from 2.6% to 2.8% [2][3] Group 2: Modern Industrial System - Progress has been made in building a modern industrial system, with a focus on strategic emerging industries such as new-generation information technology, new energy, and high-end equipment, leading to the creation of world-class industrial clusters [3][4] - The central enterprises have implemented over 800 application scenarios under the "AI+" initiative and established 1,854 smart factories, resulting in a reduction of energy consumption and carbon emissions per unit of output by 12.8% and 13.9% respectively [3][4] Group 3: Strategic Emerging Industries - Central enterprises have invested a total of 8.6 trillion yuan in strategic emerging industries during the "14th Five-Year Plan," significantly increasing their investment compared to the "13th Five-Year Plan" [4][5] - The revenue from strategic emerging industries is projected to exceed 11 trillion yuan in 2024, with contributions from new-generation information technology and high-end equipment sectors surpassing 1 trillion yuan each [5]
“十四五”以来中央企业在战略性新兴产业领域累计投资8.6万亿元
Xin Hua She· 2025-09-17 09:43
Group 1 - The core viewpoint is that central enterprises have invested a total of 8.6 trillion yuan in strategic emerging industries since the beginning of the 14th Five-Year Plan, highlighting the importance of these industries for overall development [1] - Central enterprises are focusing on strategic emerging industries as a key work area, implementing various initiatives such as industrial renewal and AI+ actions to enhance their layout in new fields [1] - Significant acceleration in the development of sectors like integrated circuits, biotechnology, and new energy vehicles has been observed, with breakthroughs in cutting-edge fields such as humanoid robots and superconducting quantum computing [1] Group 2 - In 2024, central enterprises are projected to achieve over 11 trillion yuan in revenue from strategic emerging industries, with an 8 percentage point increase in revenue contribution over the past two years [2] - The establishment of venture capital funds focusing on technology attributes and emerging fields is aimed at early, small, long-term, and hard technology investments [2] - The development of strategic emerging industries is expected to continue with increased efforts to create new pillar industries that lead future competition and enhance new productive forces [2]
“十四五”央企成绩单发布
Di Yi Cai Jing· 2025-09-17 09:22
Core Insights - Since the "14th Five-Year Plan," the total assets of central enterprises have increased from less than 70 trillion yuan to over 90 trillion yuan, with total profits rising from 1.9 trillion yuan to 2.6 trillion yuan, achieving average annual growth rates of 7.3% and 8.3% respectively [2] - The investment in strategic emerging industries has seen an average annual growth rate exceeding 20%, with over 800 application scenarios developed under the "AI+" initiative and the establishment of 1,854 smart factories as part of the digital transformation efforts [2][4] - Central enterprises have contributed over 10 trillion yuan in taxes and transferred 1.2 trillion yuan of state-owned equity to social security funds [2] Group 1: Strategic Emerging Industries - Central enterprises have focused on nine strategic emerging industries and six future industries, with cumulative investments in these sectors reaching 8.6 trillion yuan since the "14th Five-Year Plan," significantly higher than during the "13th Five-Year Plan" [4] - The revenue from strategic emerging industries is projected to exceed 11 trillion yuan in 2024, with contributions from new generation information technology and high-end equipment sectors each surpassing 1 trillion yuan [4] - Central enterprises' installed capacity for renewable energy generation accounts for approximately half of the national total, and the market size for industrial software exceeds 20% of the national market [4] Group 2: Corporate Restructuring and Integration - The State-owned Assets Supervision and Administration Commission (SASAC) has advanced the reform actions and achieved significant results, with six groups of ten enterprises undergoing strategic restructuring and nine new central enterprises being established [7][8] - The restructuring efforts focus on enhancing national security, industry leadership, and public service, with market-oriented approaches being employed to optimize the layout and structure of state-owned enterprises [8][9] - SASAC emphasizes the importance of professional, systematic, legal, and efficient supervision, implementing tailored assessment plans for central enterprises to improve operational efficiency and capital allocation [7][9]
高质量完成“十四五”规划 | “十四五”以来中央企业在战略性新兴产业领域累计投资8.6万亿元
Xin Hua She· 2025-09-17 08:24
"战略性新兴产业的持续投入,有效拓展了企业发展空间。"袁野说。 新华社北京9月17日电 国务院国资委副主任袁野17日在国新办举行的"高质量完成'十四五'规划"系列主 题新闻发布会上介绍,"十四五"以来,中央企业在战略性新兴产业领域累计投资达8.6万亿元。 袁野表示,国资央企把发展战略性新兴产业作为一项牵引性、全局性工作,深入实施中央企业产业焕 新、未来产业启航、"AI+"等专项行动,持续加强新领域新赛道布局,取得很好效果。 从具体领域来看,集成电路、生物技术、新能源汽车等领域的发展速度明显加快,人形机器人、超导量 子计算等前沿领域实现突破,工业母机、新材料等领域的托底保障能力不断增强,呈现出"梯次拓展、 合力并进"的产业发展新格局。 数据显示,2024年中央企业在战略性新兴产业领域的营业收入突破11万亿元,近两年营收贡献度提升8 个百分点,新一代信息技术、高端装备等5个领域的收入均超过万亿元。 开展产业链融通发展共链行动,以新兴产业为重点,发布供需清单近万项;设立创投基金,聚焦科技属 性、技术价值、新兴领域,积极投早、投小、投长期、投硬科技;"AI+"专项行动落地落实,一批通用 大模型、行业模型加速应用,赋能 ...
央企聚焦战略性新兴产业 ,“十四五”以来累计投资8.6万亿元
Sou Hu Cai Jing· 2025-09-17 07:01
9月17日上午,国务院新闻办公室举行"高质量完成'十四五'规划"系列主题新闻发布会,介绍砥砺奋进"十四五",中央企业高质量发展情况。 编辑 王佳箐 任卓 【来源:九派新闻】 首先是产业格局为之一新。中央企业聚焦9个战略性新兴产业和6个未来产业,结合企业资源禀赋,进行系统化布局,逐步积厚成势。"十四 五"以来,中央企业在战略性新兴产业领域的累计投资达到8.6万亿元,比"十三五"时期有了大幅提升,在集成电路、生物技术、新能源汽车等 领域的发展速度明显加快,在人形机器人、超导量子计算等前沿领域也实现了突破,在工业母机、新材料等领域的托底保障能力不断增强,总 体上呈现出"梯次拓展、合力并进"这样一种产业发展新格局。 第二是增长动能为之一新。战略性新兴产业的持续投入,有效拓展了企业发展空间。2024年中央企业在战略性新兴产业领域的营业收入突破11 万亿元,近两年营收贡献度提升8个百分点,新一代信息技术、高端装备等5个领域的收入均超过万亿元,中央企业新能源累计发电并网装机容 量约占全国的一半,工业软件市场规模占全国比例超20%。 第三是发展模式为之一新。随着战略性新兴产业的加速布局,企业发展模式也受到深刻影响。中央企业扎 ...
国资委:“十四五”以来中央企业在战新产业投资达到8.6万亿元
Xin Lang Cai Jing· 2025-09-17 03:13
9月17日,国务院国资委副主任袁野在国新办举行的"高质量完成'十四五'规划"系列主题新闻发布会上 表示,中央企业聚焦9个战略性新兴产业和6个未来产业,逐步积厚成势。"十四五"以来,中央企业在战 略性新兴产业的投资达到8.6万亿元,比"十三五"时期大幅提升。在集成电路、生物技术、新能源汽车 等领域发展速度明显加快,在人形机器人、超导量子计算等前沿领域也实现了突破。在工业母机、新材 料领域托底保障能力不断增强。总体上呈现出梯次拓展,合力并进的产业发展新格局。(人民财讯) ...
投资促进局欧洲代表处组织欧洲企业团考察铜陵
Shang Wu Bu Wang Zhan· 2025-09-16 11:48
Group 1 - The investment promotion bureau's European representative office organized a delegation of technology companies from the UK, Belgium, Italy, and Hungary to conduct investment promotion activities in Tongling City [1] - Tongling city officials, including the mayor and party secretary, welcomed the European technology companies and introduced the city's open innovation history and thriving export-oriented economy [1] - During the investment environment promotion meeting, European companies expressed their willingness to invest and cooperate in China, showcasing projects from companies like A&B Smart Materials, Hyper Wind, and Clan Healthcare [1] Group 2 - The investment promotion bureau's deputy director emphasized the vast opportunities in the Chinese market for innovation and pledged to assist companies in their investment and cooperation efforts [1] - Tongling city maintains a highly open attitude towards international cooperation and aims to create an internationalized, market-oriented, and standardized business investment environment [1] - The European delegation visited the Tongling Economic and Technological Development Zone and learned about the development of new productive forces at local companies [2]
窄幅震荡,耐心等待靴子落地
Sou Hu Cai Jing· 2025-09-16 05:27
Market Overview - A-share market showed a fluctuating and differentiated trend, with major indices mostly declining while the Sci-Tech 50 Index rose against the trend, indicating resilience in the technology growth sector [1][2] - The Hong Kong stock market continued its upward trend, with the Hang Seng Technology Index slightly rising, driven by active performances in sectors like brain-computer interfaces and biotechnology [1][2] Index Performance - A-share indices experienced notable fluctuations, with the Shanghai Composite Index closing at 3856.45 points, down 0.1%, and the Shenzhen Component Index down 0.26% at 12971.8 points; the ChiNext Index fell 0.32% to 3056.3 points, influenced by the new energy industry chain [2] - The Sci-Tech 50 Index surged 1.52% to 1360.78 points, driven by hard technology sectors such as AI chips and computing infrastructure [2] - In the Hong Kong market, the Hang Seng Index rose 0.07% to 26465.87 points, while the Hang Seng Technology Index increased by 0.39% to 6067.05 points, marking three consecutive days of gains [2] Sector Highlights and Driving Logic - The A-share market exhibited a structural characteristic of "technology leading and consumption recovering," with policy-sensitive sectors and industrial transformation aligning [3] - The retail sector led gains, with the Wande Retail Index rising 1.36%, boosted by positive developments in U.S.-China trade talks regarding TikTok [3] - The electronics and computer sectors saw significant gains, with the GPU concept maintaining strength and the logic of domestic substitution for AI chips being reinforced [3] - In the Hong Kong market, technology growth and medical innovation drove performance, with brain-computer interface concepts experiencing a surge following product certifications [3] Underperforming Sectors and Driving Logic - A-share resource cyclical stocks and previously popular sectors collectively retreated, negatively impacting market sentiment; the non-ferrous metals sector fell 2.28% [4] - The lithium battery industry chain weakened for two consecutive days due to intensified competition and rising raw material costs [4] - In the Hong Kong market, cyclical and consumer sectors showed mixed performance, with the materials index dropping 2.96% due to industrial metal price corrections [4] Investment Strategy Recommendations - The current market is at a convergence of an "event vacuum period" and a "policy observation period," with cautious sentiment prevailing ahead of the Federal Reserve's meeting [5] - For A-shares, a focus on "technology independence and consumption recovery" is recommended, particularly in AI computing infrastructure and semiconductor equipment [6] - In the Hong Kong market, structural opportunities in "technology growth and medical innovation" should be seized, with attention on AI applications and core technology barriers [6]
港股异动丨MIRXES飙升35%,再创上市新高
Ge Long Hui· 2025-09-16 02:01
Group 1 - Mirxes-B (2629.HK) experienced a significant price surge, rising over 35% to reach 75 HKD, marking a new all-time high since its IPO [1] - The company's market capitalization has surpassed 20 billion HKD [1] - Since its listing on May 23, the stock price has increased by 220% from the IPO price of 23.3 HKD [1] Group 2 - Mirxes is a Singapore-based company specializing in microRNA technology, focusing on making disease screening and diagnostic solutions accessible in key Asian markets [1] - The company was recently included in the Hang Seng Composite Index, effective from September 8, and has officially become a Hong Kong Stock Connect eligible stock [1]
新元素药业递表港交所 中信证券为独家保荐人
Zheng Quan Shi Bao Wang· 2025-09-16 00:11
基于公司结构代谢分析的药物发现平台,公司不仅推出了临床阶段候选产品ABP-671和ABP-745,更推 出了一系列临床前管线,包括AT6616、ABP-6016、ABP6118。 新元素药业是一家专注于代谢、炎症和心血管疾病疗法开发的生物技术公司。公司核心产品ABP-671是 一种URAT1抑制剂,正在中美进行2b/3期临床试验,有望成为一线痛风和高尿酸血症治疗药物。ABP- 671在治疗合并高尿酸血症CKD和难治性痛风方面也展现出临床前潜力。 新元素药业已向港交所提交上市申请,中信证券为其独家保荐人。 ...